Quince Therapeutics (NASDAQ:QNCX) Upgraded to “Sell” at Wall Street Zen

Wall Street Zen upgraded shares of Quince Therapeutics (NASDAQ:QNCX) from a strong sell rating to a sell rating in a report published on Saturday.

QNCX has been the topic of a number of other reports. D. Boral Capital downgraded Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Lucid Cap Mkts downgraded Quince Therapeutics from a “strong-buy” rating to a “strong sell” rating in a report on Friday, January 30th. lowered Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, January 29th. Maxim Group cut shares of Quince Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. Finally, Citizens Jmp downgraded shares of Quince Therapeutics from a “market outperform” rating to a “market perform” rating in a report on Friday, January 30th. Five research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Quince Therapeutics has a consensus rating of “Reduce” and a consensus target price of $65.00.

Quince Therapeutics Trading Down 1.5%

QNCX stock opened at $1.28 on Friday. The stock’s 50 day simple moving average is $1.16 and its 200 day simple moving average is $15.18. Quince Therapeutics has a 12-month low of $0.80 and a 12-month high of $45.50. The stock has a market capitalization of $20.87 million, a PE ratio of -0.08 and a beta of 1.45.

Institutional Trading of Quince Therapeutics

Several large investors have recently modified their holdings of the company. Marshall Wace LLP lifted its holdings in Quince Therapeutics by 143.7% in the fourth quarter. Marshall Wace LLP now owns 511,858 shares of the company’s stock valued at $1,715,000 after acquiring an additional 301,813 shares during the period. ADAR1 Capital Management LLC grew its stake in shares of Quince Therapeutics by 442.1% during the 3rd quarter. ADAR1 Capital Management LLC now owns 775,034 shares of the company’s stock valued at $1,263,000 after purchasing an additional 632,076 shares during the period. Goldman Sachs Group Inc. purchased a new stake in shares of Quince Therapeutics during the 4th quarter valued at about $769,000. Cerity Partners LLC purchased a new stake in shares of Quince Therapeutics during the 4th quarter valued at about $636,000. Finally, OMERS ADMINISTRATION Corp bought a new position in shares of Quince Therapeutics in the 4th quarter worth approximately $308,000. Institutional investors own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.